Newsom T Hunter, Potvin Richard
Newsom Eye & Laser Center, Sebring, FL, USA.
Science in vision, Bend, OR, USA.
Clin Ophthalmol. 2022 Jan 25;16:183-190. doi: 10.2147/OPTH.S350850. eCollection 2022.
To assess the visual outcomes and quality of vision of patients receiving the AcrySof IQ Vivity™ non-diffractive extended vision intraocular lens (NDEV IOL) after uneventful cataract surgery when the non-dominant eye is targeted for slight myopia.
Single site, prospective, single-arm study.
Eligible subjects interested in reducing their dependence on spectacles over a range of working distances were enrolled and followed for 3 months after the second eye surgery. Subjects were bilaterally implanted with this NDEV IOL, with a target of emmetropia in the dominant eye and a myopic refraction of -0.75D in the non-dominant eye. At 3 months postoperative, the uncorrected and distance-corrected (with monovision) visual acuity at 40 cm, 66 cm and 4 m were recorded, along with the manifest refraction. Questionnaires related to spectacle independence, patient satisfaction and quality of vision were also administered.
Data from 33 subjects were analyzed. The mean difference between eyes by subject was 0.80 ± 0.37 D. Twenty-nine of 33 (88%) subjects had a binocular uncorrected near VA of 0.2 logMAR or better. Twenty-five of 33 eyes (76%) had a binocular distance-corrected (-0.75 D in the non-dominant eye) VA of 0.2 logMAR or better at all three test distances. Satisfaction with vision at all distances was high. The reported level of spectacle independence was higher than for the same lens without monovision. Visual disturbances were higher than has been previously reported for this lens but were not correlated to the level of monovision.
A target of -0.75 D of myopia in the non-dominant eye of patients bilaterally implanted with this NDEV IOL improved near vision, increasing the rate of spectacle independence in patients relative to those targeted for bilateral emmetropia, with no correlated increases in visual disturbances.
评估在非优势眼目标为轻度近视的白内障手术顺利完成后,接受AcrySof IQ Vivity™非衍射扩展视觉人工晶状体(NDEV IOL)的患者的视觉结果和视觉质量。
单中心、前瞻性、单臂研究。
招募有兴趣在一系列工作距离上减少对眼镜依赖的符合条件的受试者,并在第二只眼手术后随访3个月。受试者双眼植入这种NDEV IOL,优势眼目标为正视,非优势眼目标为-0.75D近视屈光。术后3个月,记录40cm、66cm和4m处的未矫正和距离矫正(采用单眼视)视力,以及显验光。还发放了与眼镜独立性、患者满意度和视觉质量相关的问卷。
分析了33名受试者的数据。受试者双眼之间的平均差异为0.80±0.37D。33名受试者中有29名(88%)双眼未矫正近视力为0.2 logMAR或更好。33只眼中有25只(76%)在所有三个测试距离处双眼距离矫正(非优势眼为-0.75D)视力为0.2 logMAR或更好。对所有距离的视力满意度都很高。报告的眼镜独立性水平高于未采用单眼视的同一晶状体。视觉干扰高于此前该晶状体的报告水平,但与单眼视水平无关。
双眼植入这种NDEV IOL的患者,非优势眼目标为-0.75D近视改善了近视力,相对于目标为双眼正视的患者,提高了眼镜独立性,且视觉干扰没有相应增加。